ArticleFrontiers in oncology2026
An exploration of GuaLouQuMaiWan related novel prognostic model and search for potential compound pachymic acid in bladder cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Bladder cancer (BC) is a highly prevalent malignant tumor. The traditional Chinese medicine formula Guo Lou Qu Mai Wan (GLQMW), when used in conjunction with chemotherapy, has been shown to reduce adverse reactions and prolong survival time, although its specific mechanisms remain unclear. This study aims to investigate whether GLQMW exerts its therapeutic effects on bladder cancer by modulating the tumor immune microenvironment. Methods: To elucidate the molecular mechanisms of GLQMW, we employed bioinformatics analysis, systems pharmacology, and molecular docking to explore the prognostic value of GLQMW-related target genes for BC and to establish a prognostic prediction model. We analyzed the relationship between GLQMW-related target genes and immune cell infiltration, as well as the compositional differences of immune cell subpopulations across different risk groups. Molecular docking was used to screen for pachymic acid (PA) as the main anticancer active compound, and CCK8 and western blot were used to determine the target of PA as the active compound. Result: In our immune infiltration analysis, the expression levels of five genes (MAPK12, MAN1B1, EGFR, FABP6, and ZAP70) were found to be associated with immune cells. Moreover, a higher presence of naïve B cells, plasma cells, CD8+ T cells, and Tregs was observed in the low-risk group, indicating that GLQMW can significantly impact the immune microenvironment by targeting these five model genes, thereby exerting therapeutic effects. In the single-cell data analysis, our results demonstrated that the percentage of CD8 T+ cells and plasma cells in tumor tissue was significantly lower than that in adjacent non-tumor tissue. In addition, through drug similarity analysis and molecular docking, we identified PA as a potential anti-tumor compound. Furthermore, PA was validated Conclusions: PA, the active ingredient of GLQMW, can inhibit BC by inhibiting EGFR and upregulating FABP6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.